GlassScriptPhysician profile
Mark D Hubbard
NPI 1508886730
$4,616.29
in general payments reported to CMS, 2019-2025
29 companies · $1,289 in 2025
The $1,289 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2022: $784 · 2023: $1,214 · 2024: $1,144 · 2025: $1,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $848.50 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $700.66 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $628.60 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $578.02 | 2022-2025 | |
| Glaxosmithkline, LLC. | $289.58 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $205.31 | 2023-2025 | |
| Genzyme Corporation | $185.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $142.20 | 2023 | Dupixent, Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $134.75 | 2022-2024 | |
| Dexcom, INC. | $133.81 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.19 | 2023-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $109.70 | 2022-2024 | Freestyle Libre 3, Octrode |
| Kowa Pharmaceuticals America, INC. | $72.69 | 2025 | Zoryve |
| Gilead Sciences, INC. | $52.83 | 2024 | |
| Boston Scientific Corporation | $47.76 | 2025 | Wavewriter Alpha Prime 16 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.76 | 2022-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $42.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.56 | 2022 | |
| Esperion Therapeutics, INC. | $29.70 | 2022-2023 | Nexletol |
| Eisai INC. | $26.67 | 2024 | |
| Teleflex LLC | $23.92 | 2025 | Barrigel |
| Hologic Sales and Service, LLC | $22.74 | 2025 | Aptima |
| Astellas Pharma US INC | $18.55 | 2024 | Veozah |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Inspire Medical Systems, INC. | $16.96 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $15.27 | 2022 | |
| Merck Sharp & Dohme LLC | $14.58 | 2025 | Gardasil 9, M-M-R II, Capvaxive |
| Idorsia Pharmaceuticals US INC | $14.46 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.